NCI and FDA are recruiting three medical oncologists who would divide their time between clinical and regulatory duties—half at the FDA Office of Oncology and Hematology Products, and half at the NCI Center for Cancer Research.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
